Heart Failure Management with Beta-Blockers
Evidence-Based Beta-Blocker Selection
- The European Society of Cardiology recommends bisoprolol, carvedilol, metoprolol succinate, for patients with heart failure with reduced ejection fraction (HFrEF) 4
- Only three beta-blockers have demonstrated mortality reduction in HFrEF: bisoprolol, carvedilol, and metoprolol succinate (extended-release) 1, 3
- These specific beta-blockers have been extensively studied in large randomized controlled trials showing significant reductions in mortality and hospitalizations 1, 2
Preferred Beta-Blockers for Heart Failure
- Carvedilol has shown superior mortality reduction compared to immediate-release metoprolol tartrate in the COMET trial (17% greater mortality reduction) 3
- Bisoprolol demonstrated a 32% reduction in all-cause mortality in NYHA class III or IV heart failure patients in the CIBIS-II trial 3
- Metoprolol succinate (extended-release) showed a 34% reduction in mortality in the MERIT-HF trial 3
Initiation and Titration of Appropriate Beta-Blockers
- Beta-blockers should be initiated at low doses and gradually titrated up to target doses used in clinical trials 1, 2
- Beta-blockers should be used in conjunction with ACE inhibitors/ARBs and diuretics as part of comprehensive heart failure management 1, 2